Table 2.
The association between TSpolymorphism and clinical outcomes
| Study (reference) | RR (n/N) | OS (HR, 95% CI) | Toxicity |
|---|---|---|---|
| Goekkurt 2006 [11] |
3R3R: 3/12; 2R2R+2R3R: 9/32 |
NR |
NR |
| Ruzzo 2006 [14] |
3R3R: 22/61; 2R2R+2R3R: 48/114 |
NR |
NR |
| Han 2010 [19] |
3R3R: 16/28; 2R2R+2R3R: 5/10 |
NR |
NR |
| Seo 2009 [21] |
NR |
NR |
NSS |
| Shitara 2010 [27] |
NR |
(2R2R+2R3R)/3R3R: 1.28 (0.85, 1.96) |
NSS |
| Huang 2009 [28] |
NR |
(2R2R+2R3R)/3R3R: 1.54 (0.879, 2.698) |
NR |
| Ishida 2002 [29] |
NR |
(2R2R+2R3R)/3R3R: 1.26 (0.81, 1.95) |
NR |
| Goekkurt 2009 [31] |
3R3R: 17/33; 2R2R+2R3R: 35/101 |
NR |
Grade 3/4 leukopenia: P=0.047 |
| Ott 2006 [32] |
3R3R: 10/41; 2R2R+2R3R: 23/94 |
2R2R/3R3R: 0.33 (0.22, 0.51); 2R3R/3R3R: 0.52 (0.37, 0.74) |
NR |
| Lee 2005 [34] |
NR |
(2R2R+2R3R)/3R3R: 1.16 (0.68, 1.99) |
NR |
| Combined analysis(OR/HR, 95CI %) | OR: (2R2R+2R3R)/3R3R |
(2R2R+2R3R)/3R3R |
___ |
| Total: 0.92 (0.62, 1.37); |
Total: 1.29 (1.02, 1.64) |
|
|
| RECIST subgroup: 0.93 (0.33, 2.63); |
All studies reported the data were Asian |
|
|
| Others subgroup: 0.92 (0.60, 1.41); |
Palliative subgroup: 1.16 (0.68, 1.98) |
|
|
| Asian subgroup: 0.75 (0.18, 3.19); |
Adjuvant subgroup: 1.33 (1.02, 1.73) |
|
|
| European subgroup: 0.94 (0.62, 1.41) |
|
|
|
| Palliative subgroup: 0.90 (0.58, 1.40) |
|
|
|
| Neoadjuvant subgroup: 1.00 (0.43, 2.36) |
RR: response rate; OS: overall survival; OR: odds ratio; HR: hazard ratio; NR: not reporting; NSS: no statistical significance.